Le Lézard
Classified in: Health
Subjects: PER, PET, ANW

ISABELLE MONGEAU JOINS VETOQUINOL AS COUNTRY MANAGER FOR CANADA


LAVALTRIE, QC, Jan. 20, 2022 /CNW Telbec/ - Vetoquinol today announced the appointment of Isabelle Mongeau as Country Manager for Canada.  Mongeau's goal is to accelerate the strategic growth of Vetoquinol in the Canadian Companion and Food Producing Animal markets.

 

Isabelle brings a tremendous amount of leadership and experience to our go-to-market strategy.

Mongeau joins Vetoquinol from Nikon Optical, where she most recently served as CEO for Canada and the USA. During her 7-year tenure, Mongeau was a driving force behind the realignment of strategic plans and organizational structures to accelerate growth across all customer segments in a rapidly changing market.  Prior to Nikon Optical, Mongeau spent 13 years at Pfizer Canada.  During this time, she progressively held various leadership positions in marketing, continuing health education and sales, successfully launching several innovative iconic brands such as Viagra.  She holds a bachelor's degree in Marketing from University of Quebec at Montreal.

''We are thrilled to have Isabelle Mongeau join Vetoquinol as our Country Manager for Canada.  Her vast 25-year experience in the healthcare industry and her passion for marketing, sales and customer centricity, make her a valuable addition to the team.  Isabelle brings a tremendous amount of leadership and experience to our go-to-market strategy,'' said Stéphane Villemin, Group Director, Export Australasia, Latin America and Canada, at Vetoquinol.

ABOUT VETOQUINOL

Vetoquinol is a leading international animal health company with operations in Europe, the Americas and Asia/Pacific. An independent " pure player," Vetoquinol innovates, develops and markets veterinary drugs and non-medicinal products for food-producing animals (bovines, swine) and companion animals (dogs, cats). Since its creation in 1933, Vetoquinol has been combining innovation and geographical diversification. The strengthening of the product portfolio and the acquisitions made in high-potential territories ensure hybrid growth for the Group. As of September 30, 2021, Vetoquinol employed 2,540 people. Vetoquinol has been listed on Euronext Paris since 2006 (stock code: VETO).  Learn more about our journey and products by visiting www.vetoquinol.ca.

SOURCE Vétoquinol Canada


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...



News published on and distributed by: